Selank Prices

Selank (TP-7) is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW ≈ 751.9 Da) engineered in 1990s Russia by extending the natural immune peptide tuftsin with a Pro-Gly-Pro tail to make it metabolically stable.

It is an anxiolytic and nootropic that works through several systems at once, GABAergic and serotonergic modulation, BDNF-driven neuroplasticity, enkephalin stabilization, and immune signaling, rather than saturating a single receptor.

Unusually for a nootropic peptide, it has actual human clinical trials: head-to-head comparisons against the benzodiazepines medazepam and phenazepam showed comparable anxiety reduction WITHOUT sedation, tolerance, or withdrawal.

It is an approved prescription anxiolytic in Russia (2009, marketed as Selanc 0.15% nasal spray) but is NOT FDA-approved in the US and not approved by the EMA, MHRA, Health Canada, or TGA.

The evidence base is stronger than most peptides in this space but weaker than Western pharmaceuticals: trials were Russian, small, mostly in Russian-language journals, and not independently replicated.

PeptidePrices safety rating

8/10 · Approved in Russia

Mechanism

Synthetic analogue of tuftsin; modulates GABA-A receptor activity; increases BDNF expression; regulates serotonin, dopamine, and enkephalin metabolism; anxiolytic without sedation.

Research areas

Anxiety and stress reduction; cognitive enhancement; antidepressant effects; nootropic; immune modulation; PTSD; sleep improvement.

Regulatory / research status

Research / preclinical only

Half-life

~30 minutes; intranasal route preferred for direct CNS delivery.

Storage

Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.

Reported side effects

Very well-tolerated. Minimal side effects reported. Slight sedation possible. Nasal irritation with intranasal use.